Investors should monitor prescription ramp-up and payer coverage trends for TONMYA, as successful commercial execution could significantly increase Tonix’s revenue and market valuation. The 2034/2035 patent exclusivity provides a long runway for monetization.
Price Chart
Executive Summary
Tonix Pharmaceuticals presented new Phase 3 data at the 2026 AAPM PainConnect Annual Meeting supporting the efficacy and safety of TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, reinforcing its role as a first-in-class, non-opioid treatment. The drug, approved by the FDA in August 2025 and commercially launched in November 2025, demonstrated statistically significant pain reduction and clinically meaningful improvements in patient outcomes. This press release serves to bolster physician and market confidence in TONMYA’s therapeutic profile.
Key Facts
- TONMYA was FDA-approved on August 15, 2025, for the treatment of fibromyalgia in adults.
- Commercial launch in the U.S. occurred in November 2025.
- Phase 3 RESILIENT trial included 457 patients and showed statistically significant reduction in mean daily pain at 14 weeks.
- TONMYA is the first new FDA-approved fibromyalgia treatment in over 15 years.
- Patents provide U.S. market exclusivity until 2034/2035.
- Most common adverse events were mild oral cavity reactions, with low study withdrawal rates.
Financial Impact
Potential to capture meaningful share of the 6–12 million-patient U.S. fibromyalgia market; no revenue figures disclosed but commercial momentum is building.
Risk Factors
- Limited sales and revenue data available; commercial success is not guaranteed.
- Competition from existing fibromyalgia therapies and off-label use of generic cyclobenzaprine.
- Potential safety monitoring due to warnings for serotonin syndrome, embryofetal toxicity, and CNS depression.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252331 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers